zasocitinib
Sponsor Takeda Pharmaceutical CO LTD · listed as TAK
zasocitinib is a drug asset sponsored by Takeda Pharmaceutical CO LTD, listed as TAK. CSA tracks 2 forward catalysts for it — the nearest is a readout expected May 18, 2027 (day precision, medium confidence), tied to trial NCT06671483. That trial is in Phase 3 and currently recruiting, studying Psoriatic Arthritis. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for zasocitinib
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-05-18 | READOUT | medium | NCT06671483 |
| 2027-05-30 | READOUT | medium | NCT07752108 |
Trials for zasocitinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06671483 catalyst | Phase 3 | Recruiting | 2027-05-18 | Experimental | Takeda | Psoriatic Arthritis |
| NCT06671496 | Phase 3 | Recruiting | 2027-05-18 | Experimental | Takeda | Psoriatic Arthritis |
| NCT07752108 catalyst | Phase 3 | Not yet recruiting | 2027-05-30 | Experimental | Takeda | Palmoplantar Psoriasis |
| NCT06550076 | Phase 3 | Active, not recruiting | 2029-08-05 | Experimental | Takeda | Plaque Psoriasis |
| NCT07286058 | Phase 3 | Recruiting | 2029-12-18 | Experimental | Takeda | Psoriatic Arthritis |
| NCT07250802 | Phase 3 | Recruiting | 2033-01-24 | Experimental | Takeda | Plaque Psoriasis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More TAK catalysts